Cipla Recalls Levalbuterol Inhalation Solution Vials for Impurity Failure
Cipla Limited is recalling 140,625 vials of Levalbuterol Inhalation Solution because the product failed impurity specifications. The affected lot is distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The agency classified this as an FDA Class III recall, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Cipla Limited is recalling 140,625 vials of Levalbuterol Inhalation Solution, USP, 0.31 mg/3 mL. The product is a prescription-only medication manufactured by Cipla Ltd. in India for Dr. Reddy's Laboratories, Inc. The specific lot number is FA4022, with an expiration date of December 2015.
The recall was initiated because the product is out of specification for a known degradant, which is a type of impurity or degradation product. The agency has classified this recall as Class III, indicating that use of or exposure to the product is not likely to cause adverse health consequences.
The affected product was distributed nationwide in the United States, including Puerto Rico. Patients and healthcare providers should stop using the affected vials and contact their healthcare provider or pharmacist for guidance on obtaining a replacement.
The recalled product
- Product
- Levalbuterol Inhalation Solution, USP, 0.31 mg/ 3 mL, 3 mL Vials, Rx Only. Manufactured by: Cipla Ltd. Plot 9 & 10, Indure, SEZ, Pithampur, M.P.-454 775, INDIA, Manufactured for: Dr. Reddy's Laboratories, Inc., Princeton NJ 08640. NDC: 43598-412-25.
- Manufacturer
- Cipla Limited
- Category
- Drug — Inhalation Solution
- Hazard
- Affected units
- 140,625
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: FA4022
- Expiry: December 2015.
Distribution
Related recalls
Same manufacturer · Cipla Limited
See all →- ModeratePhytonadione injectable emulsion vials recalled after failing stability testing specifications
FDA (Drugs) · 2025-12-10
- ModerateCipla Recalls Nevirapine Extended Release Tablets for Dissolution Failure
FDA (Drugs) · 2018-12-26
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17